vs

Side-by-side financial comparison of CARLISLE COMPANIES INC (CSL) and ResMed (RMD). Click either name above to swap in a different company.

ResMed is the larger business by last-quarter revenue ($1.4B vs $1.1B, roughly 1.4× CARLISLE COMPANIES INC). ResMed runs the higher net margin — 27.6% vs 12.1%, a 15.5% gap on every dollar of revenue. On growth, ResMed posted the faster year-over-year revenue change (11.0% vs -4.0%). Over the past eight quarters, ResMed's revenue compounded faster (7.8% CAGR vs -14.8%).

Carlisle Companies Incorporated is a supplier of construction products that make buildings more energy efficient and resilient. The company manufactures and sells single-ply roofing products as well as warranted systems and accessories for the commercial building industry. The company is organized into two segments, including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing unde...

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

CSL vs RMD — Head-to-Head

Bigger by revenue
RMD
RMD
1.4× larger
RMD
$1.4B
$1.1B
CSL
Growing faster (revenue YoY)
RMD
RMD
+15.0% gap
RMD
11.0%
-4.0%
CSL
Higher net margin
RMD
RMD
15.5% more per $
RMD
27.6%
12.1%
CSL
Faster 2-yr revenue CAGR
RMD
RMD
Annualised
RMD
7.8%
-14.8%
CSL

Income Statement — Q1 FY2026 vs Q4 FY2026

Metric
CSL
CSL
RMD
RMD
Revenue
$1.1B
$1.4B
Net Profit
$127.7M
$392.6M
Gross Margin
34.5%
61.8%
Operating Margin
17.1%
34.6%
Net Margin
12.1%
27.6%
Revenue YoY
-4.0%
11.0%
Net Profit YoY
-10.9%
13.9%
EPS (diluted)
$3.10
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSL
CSL
RMD
RMD
Q2 26
$1.4B
Q1 26
$1.1B
$1.4B
Q4 25
$1.1B
$1.4B
Q3 25
$1.3B
$1.3B
Q2 25
$1.4B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.1B
$1.3B
Q3 24
$1.3B
$1.2B
Net Profit
CSL
CSL
RMD
RMD
Q2 26
$392.6M
Q1 26
$127.7M
$398.7M
Q4 25
$127.4M
$392.6M
Q3 25
$214.2M
$348.5M
Q2 25
$255.8M
$379.7M
Q1 25
$143.3M
$365.0M
Q4 24
$162.8M
$344.6M
Q3 24
$244.3M
$311.4M
Gross Margin
CSL
CSL
RMD
RMD
Q2 26
61.8%
Q1 26
34.5%
62.2%
Q4 25
33.8%
61.8%
Q3 25
36.0%
61.5%
Q2 25
37.3%
60.8%
Q1 25
35.2%
59.3%
Q4 24
36.1%
58.6%
Q3 24
38.6%
58.6%
Operating Margin
CSL
CSL
RMD
RMD
Q2 26
34.6%
Q1 26
17.1%
34.9%
Q4 25
16.8%
34.6%
Q3 25
21.8%
33.4%
Q2 25
23.1%
33.7%
Q1 25
16.8%
33.0%
Q4 24
19.9%
32.5%
Q3 24
23.7%
31.6%
Net Margin
CSL
CSL
RMD
RMD
Q2 26
27.6%
Q1 26
12.1%
27.9%
Q4 25
11.3%
27.6%
Q3 25
15.9%
26.1%
Q2 25
17.6%
28.2%
Q1 25
13.1%
28.3%
Q4 24
14.5%
26.9%
Q3 24
18.3%
25.4%
EPS (diluted)
CSL
CSL
RMD
RMD
Q2 26
$2.68
Q1 26
$3.10
$2.74
Q4 25
$3.06
$2.68
Q3 25
$4.98
$2.37
Q2 25
$5.88
$2.58
Q1 25
$3.20
$2.48
Q4 24
$3.76
$2.34
Q3 24
$5.25
$2.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSL
CSL
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$771.3M
$1.4B
Total DebtLower is stronger
$663.8M
Stockholders' EquityBook value
$1.7B
$6.3B
Total Assets
$8.5B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSL
CSL
RMD
RMD
Q2 26
$1.4B
Q1 26
$771.3M
$1.7B
Q4 25
$1.1B
$1.4B
Q3 25
$1.1B
$1.4B
Q2 25
$68.4M
$1.2B
Q1 25
$220.2M
$932.7M
Q4 24
$753.5M
$521.9M
Q3 24
$1.5B
$426.4M
Total Debt
CSL
CSL
RMD
RMD
Q2 26
$663.8M
Q1 26
$664.1M
Q4 25
$2.9B
$403.9M
Q3 25
$2.9B
$408.7M
Q2 25
$1.9B
$658.4M
Q1 25
$1.9B
$663.1M
Q4 24
$1.9B
$662.9M
Q3 24
$2.3B
$667.6M
Stockholders' Equity
CSL
CSL
RMD
RMD
Q2 26
$6.3B
Q1 26
$1.7B
$6.5B
Q4 25
$1.8B
$6.3B
Q3 25
$2.0B
$6.1B
Q2 25
$2.1B
$6.0B
Q1 25
$2.2B
$5.5B
Q4 24
$2.5B
$5.3B
Q3 24
$2.8B
$5.2B
Total Assets
CSL
CSL
RMD
RMD
Q2 26
$8.5B
Q1 26
$8.8B
Q4 25
$6.3B
$8.5B
Q3 25
$6.5B
$8.3B
Q2 25
$5.5B
$8.2B
Q1 25
$5.5B
$7.6B
Q4 24
$5.8B
$7.1B
Q3 24
$6.5B
$7.2B
Debt / Equity
CSL
CSL
RMD
RMD
Q2 26
0.11×
Q1 26
0.10×
Q4 25
1.61×
0.06×
Q3 25
1.45×
0.07×
Q2 25
0.89×
0.11×
Q1 25
0.87×
0.12×
Q4 24
0.77×
0.13×
Q3 24
0.83×
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSL
CSL
RMD
RMD
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-73.0M
FCF MarginFCF / Revenue
-6.9%
Capex IntensityCapex / Revenue
2.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$924.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSL
CSL
RMD
RMD
Q2 26
Q1 26
Q4 25
$386.0M
$339.7M
Q3 25
$426.9M
$457.3M
Q2 25
$287.1M
$538.8M
Q1 25
$1.8M
$578.7M
Q4 24
$370.6M
$308.6M
Q3 24
$312.8M
$325.5M
Free Cash Flow
CSL
CSL
RMD
RMD
Q2 26
Q1 26
$-73.0M
Q4 25
$346.1M
$311.2M
Q3 25
$393.4M
$414.4M
Q2 25
$258.3M
$508.2M
Q1 25
$-27.2M
$557.9M
Q4 24
$334.0M
$288.0M
Q3 24
$293.5M
$307.7M
FCF Margin
CSL
CSL
RMD
RMD
Q2 26
Q1 26
-6.9%
Q4 25
30.7%
21.9%
Q3 25
29.2%
31.0%
Q2 25
17.8%
37.7%
Q1 25
-2.5%
43.2%
Q4 24
29.7%
22.5%
Q3 24
22.0%
25.1%
Capex Intensity
CSL
CSL
RMD
RMD
Q2 26
Q1 26
2.7%
Q4 25
3.5%
2.0%
Q3 25
2.5%
3.2%
Q2 25
2.0%
2.3%
Q1 25
2.6%
1.6%
Q4 24
3.3%
1.6%
Q3 24
1.4%
1.5%
Cash Conversion
CSL
CSL
RMD
RMD
Q2 26
Q1 26
Q4 25
3.03×
0.87×
Q3 25
1.99×
1.31×
Q2 25
1.12×
1.42×
Q1 25
0.01×
1.59×
Q4 24
2.28×
0.90×
Q3 24
1.28×
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSL
CSL

CCM$758.0M72%
CWT$294.0M28%

RMD
RMD

Segment breakdown not available.

Related Comparisons